Shah Capital pushes for Novavax (NVAX) sale

Shah Capital is urging Novavax (NASDAQ: NVAX) board to pursue a sale, according to a Reuters report on Tuesday.

• The fund is citing a third consecutive year of poor roll-out of its COVID-19 shot.
• Shah Capital owns a 7.2% stake in the company and is the second largest shareholders.

You May Also Be Interested In

• Apple alleges defendant in trade secret case against OpenAI accessed power converter circuit schematic while at OpenAI - legal filing
• AWS and Azure launch private multicloud connectivity service
• Activist hedge fund Engine Capital has built a 1.5% stake in EPAM Systems - Reuters